Comparison

iGeriatrics vs Maudsley Deprescribing Guide

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

iGeriatrics

This app consolidates clinical tools and references from the American Geriatrics Society for healthcare providers. It offers quick guides on diabetes management, immunizations, cultural considerations, and psychiatric consultations for older adults. It also includes cognitive screening tools and information on managing atrial fibrillation.

Highlights
  • Geriatrics 5Ms Quick Guide
  • Diabetes Management Guide
  • Cultural Navigator
  • Immunization Information
  • GeriPsych Consult
  • Cognitive Screening Toolkit
  • Atrial Fibrillation Management
Features
Read full description

iGeriatrics combines American Geriatrics Society's clinical tools & references into one free, easy to use application. iGeriatrics is an excellent AGS resource for all healthcare providers taking care of older adults. • Geriatrics 5Ms Quick Guide provides a framework for caring for older adults that aligns with the 4Ms of Age Friendly Health Systems. • Quick Guide to Diabetes Management provides a 5-step framework on diabetes management in older adults, and is based on the recommendations from the American Diabetes Association and the American Geriatrics Society. • Geriatrics Cultural Navigator offers quick guidance on issues and concerns regarding the beliefs, traditions, and customs that would apply to clinical encounters with older adults of diverse ethnic backgrounds. • Quick Guide to Common Immunizations includes essential information about must-have vaccines for older adults. • GeriPsych Consult was developed to assist healthcare providers in managing psychotic symptoms and disorders in older adults. • Cognitive Screening Toolkit provides access to ten cognitive screening tests that are recommended by the USPSTF. This toolkit can help in selecting the appropriate cognitive screening tool to use with primary care patients. • Management of Atrial Fibrillation discusses the recommendations of the American College of Cardiology (ACC), the American Heart Association (AHA) and the European Society of Cardiology (ESC) Guidelines and their effectiveness in managing AF to prevent strokes. It lists the risks and benefits of treatment options and describes the co-morbidities and geriatric syndromes common among older adults with AF. Privacy Policy: https://geriatricscareonline.org/static/privacypolicy Terms of Use: https://geriatricscareonline.org/static/terms

About

Maudsley Deprescribing Guide

This app offers evidence-based guidance for healthcare professionals and interested individuals on safely discontinuing psychiatric medications. It covers antidepressants, benzodiazepines, gabapentinoids, and Z-drugs, providing principles, tapering regimens, and troubleshooting for withdrawal symptoms. The free version includes sample content, with full access available via in-app purchase.

Highlights
  • Evidence-based deprescribing guidelines
  • Covers antidepressants, benzodiazepines, gabapentinoids, Z-drugs
  • Patient-centered approach
  • Distinguishes withdrawal from underlying symptoms
  • Hyperbolic tapering guidance
  • Step-by-step tapering regimens
  • Troubleshooting withdrawal issues
Features
Read full description

"Try before you buy"-Download the FREE App,which includes sample content. In-App purchase required to unlock all content. The Maudsley Deprescribing Guidelines provide evidence-based recommendations for safely discontinuing antidepressants, benzodiazepines, gabapentinoids, and Z-drugs. This resource is essential for healthcare professionals aiming to optimize patient care and minimize medication-related harm. It emphasizes a patient-centered approach, ensuring that deprescribing is conducted thoughtfully and effectively. Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as: - Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs - Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process - Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat - The difference between physical dependence and addiction/substance use disorder - Explanation of why and how to implement hyperbolic tapering in clinical practice - Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches - Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual - Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse. - Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine. Disclaimer : App developers do not endorse or recommend any specific medications. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Content licensed from printed ISBN 10: 1119823021 Content licensed from printed ISBN 13: 9781119823025 If you have any questions or comments,email us any time:customersupport@skyscape.com or call 508-299-3000 Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms & Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx Author:Deanna Mark Horowitz; David M. Taylor Publisher:Wiley-Blackwell

Screenshots

iGeriatrics4 screens
Maudsley Deprescribing Guide4 screens

Verdict

The call

The clearest difference is rating: iGeriatrics at 4.8 against Maudsley Deprescribing Guide's 1.0. iGeriatrics also leads on in-app purchases (none vs 1) and ads (none vs shown). Maudsley Deprescribing Guide's advantage is iOS requirement (13.0 vs 15.6). On price and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Maudsley Deprescribing Guide sells 1 one-off in-app purchase. iGeriatrics asks for nothing beyond the download.

ReceptionRating · Positive reviews · Number of ratings

iGeriatrics holds the better App Store score, 4.8 against 1.0. That said, the two scores are not equally well evidenced: iGeriatrics has 114 ratings behind it against 1, so its average is the more settled of the two. Written reviews point the same way: 24% of iGeriatrics's written reviews are positive against 0% of Maudsley Deprescribing Guide's.

Scorecard7 real differences · 3 level
iGeriatrics versus Maudsley Deprescribing Guide: the parameters behind the verdict, then further details
ParameteriGeriatricsMaudsley Deprescribing Guide
PriceFreeFree
Rating4.8 (114 ratings) — better1.0 (1 ratings)
Positive reviews23.5% of reviews — better0.0% of reviews
Number of ratings114 — better1
Update frequencyEvery 11 months—
AdsNo — betterYes
In-app purchasesNo — betterYes
MonetizationFree — betterFree with in-app purchases
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS15.613.0 — better
Further details — not scored
Size34 MB149 MB
Age rating17+17+
DeveloperAmerican Geriatrics SocietySkyscape Medpresso Inc

Customer experience

iGeriatrics

All ratings112 ratings
Positive93.8%
Neutral1.8%
Negative4.5%
Written reviews17 reviews
Positive23.5%
Neutral17.6%
Negative58.8%

Maudsley Deprescribing Guide

All ratings1 ratings
Positive0.0%
Neutral0.0%
Negative100.0%
Written reviews1 reviews
Positive0.0%
Neutral0.0%
Negative100.0%

In-app purchases

None

iGeriatrics

No in-app purchases

1 purchases

Maudsley Deprescribing Guide

One-time1
  • Maudsley Deprescribing Guide$48.99

Questions

Is iGeriatrics free?
iGeriatrics is free to download, with no in-app purchases.
Is Maudsley Deprescribing Guide free?
Maudsley Deprescribing Guide is free to download, with in-app purchases available.
Which has better reviews, iGeriatrics or Maudsley Deprescribing Guide?
iGeriatrics is rated higher. iGeriatrics averages 4.8 out of 5 from 114 ratings, while Maudsley Deprescribing Guide averages 1.0 from 1 ratings.
Do iGeriatrics or Maudsley Deprescribing Guide have ads?
Maudsley Deprescribing Guide shows ads; iGeriatrics does not.

Other comparisons